Washington D.c., DC19 Active Studies

Erectile Dysfunction Clinical Trials in Washington D.c., DC

Find 19 actively recruiting erectile dysfunction clinical trials in Washington D.c., DC. Connect with local research sites and explore new treatment options.

19
Active Trials
16
Sponsors
5,700
Enrolling

Recruiting Erectile Dysfunction Studies in Washington D.c.

RecruitingWashington D.c., DCNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingWashington D.c., DCNCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

680 participants
Immunocore Ltd
View Study Details
RecruitingWashington D.c., DCNCT06994442

Optimizing Pain Treatment in Children On Mechanical Ventilation

In this clinical trial, investigators want to learn more about using non-opioid pain medications for children with acute respiratory failure. Right now, doctors give these children opioids to help wit...

644 participants
Weill Medical College of Cornell University
View Study Details
RecruitingWashington D.c., DCNCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine....

640 participants
Pfizer
View Study Details
RecruitingWashington D.c., DCNCT05267821

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

500 participants
Nationwide Children's Hospital
View Study Details
RecruitingWashington D.c., DCNCT05077904

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no re...

350 participants
UCB Biopharma SRL
View Study Details
RecruitingWashington D.c., DCNCT05315700

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

350 participants
ORIC Pharmaceuticals
View Study Details
RecruitingWashington D.c., DCNCT05156983

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagu...

328 participants
Takeda
View Study Details
RecruitingWashington D.c., DCNCT05434234

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

312 participants
MediLink Therapeutics (Suzhou) Co., Ltd.
View Study Details
RecruitingWashington D.c., DCNCT06384807

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

280 participants
Biohaven Therapeutics Ltd.
View Study Details
RecruitingWashington D.c., DCNCT05443126

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)...

265 participants
Ellipses Pharma
View Study Details
RecruitingWashington D.c., DCNCT06425159

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label...

242 participants
Biohaven Therapeutics Ltd.
View Study Details
RecruitingWashington D.c., DCNCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingWashington D.c., DCNCT05135975

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, a...

86 participants
Nationwide Children's Hospital
View Study Details
RecruitingWashington D.c., DCNCT05785819

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...

60 participants
Veralox Therapeutics
View Study Details
RecruitingWashington D.c., DCNCT05345197

Emicizumab in Patients With Acquired Hemophilia A

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquire...

51 participants
University of Washington
View Study Details
RecruitingWashington D.c., DCNCT04865887

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is...

35 participants
Georgetown University
View Study Details
RecruitingWashington D.c., DCNCT06712875

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, ...

27 participants
Ann & Robert H Lurie Children's Hospital of Chicago
View Study Details
RecruitingWashington D.c., DCNCT06701812

Digoxin Medulloblastoma Study

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients....

23 participants
H. Lee Moffitt Cancer Center and Research Institute
View Study Details

About Erectile Dysfunction Clinical Trials in Washington D.c.

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 19 erectile dysfunction clinical trials recruiting participants in Washington D.c., DC. These studies are seeking a combined 5,700 participants. Research is being sponsored by Immunocore Ltd, Weill Medical College of Cornell University, Pfizer and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Washington D.c. — FAQ

Are there erectile dysfunction clinical trials in Washington D.c.?

Yes, there are 19 erectile dysfunction clinical trials currently recruiting in Washington D.c., DC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Washington D.c.?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Washington D.c. research site will contact you about next steps.

Are clinical trials in Washington D.c. free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Washington D.c. studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 19 active trials in Washington D.c. are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated March 2, 2026 from ClinicalTrials.gov